Navigation Links
BioSpecifics Technologies Corp. Reports Second Quarter 2011 Financial Results

LYNBROOK, N.Y., Aug. 9, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Eurasia, today announced its financial results for the second quarter ended June 30, 2011 and provided a corporate update. For the quarter, the Company reported net income of $2.6 million or $0.40 per share on a basic basis and $0.36 on a fully diluted basis and the Company anticipates that it will be profitable on an ongoing annual basis.

“We are very pleased to report strong financial results this quarter and our expectation of continued profitability. We are also enthusiastic about the steady commercial progress that has been made by Pfizer in commercializing XIAPEX for the treatment of Dupuytren’s contracture in Europe,” reflected Thomas L. Wegman, President of BioSpecifics. “In addition as we have previously reported, enrollment is complete for the Phase 3 pivotal trials for XIAFLEX for the treatment of Peyronie's disease, and we anticipate announcing those top-line results in the second quarter of next year.”

Financial ResultsBioSpecifics reported net income of $2.6 million for the second quarter of 2011, or $0.40 per basic and $0.36 per diluted  share, compared to a net loss of $0.9 million, or $0.15 per basic and diluted common share, for the same period in 2010. The Company anticipates that it will be profitable on an ongoing annual basis.

Total revenue for the second quarter of 2011 was $5.0 million, compared to $0.9 million for the same period in 2010.

Royalty and earn-out revenues for the second quarter of 2011 were $1.7 million, compared to $0.5 million for the same period in 2010. Royalty and cost of goods sold revenues recognized under the Company’s agreement with Auxilium Pharmaceuticals, Inc. (Auxilium) for the second quarter of 2011 were $1.1 million, compared to $0 million for the same period in 2010. Royalty revenues recognized from DFB Biotech, Inc. for the second quarter of 2011 were $0.6 million compared with $0.5 million for the same period in 2010.

Licensing revenue recognized from Auxilium for the second quarters of 2011 and 2010 was $0.1 million in each period. These licensing revenues related to cash payments received in prior years and amortized over the expected development period.

Milestone revenue recognized from Auxilium for the second quarter of 2011 was $3.2 million, compared to $0.15 million for the same period in 2010. In the second quarter of 2011 BioSpecifics received and recognized $2.6 million of the $30 million regulatory milestone paid to Auxilium by its licensee Pfizer, Inc. (Pfizer) following the first sale of XIAPEX (the European trade name for injectable collagenase) in a major European Union market for Dupuytren’s contracture. BioSpecifics also received and recognized a milestone of $0.6 million of the $7.5 million paid to Auxilium by Pfizer for the launch in Germany of XIAPEX in the second quarter of 2011. In the second quarter of 2010, BioSpecifics received and recognized the remaining $150,000 of a $1.0 million milestone related to the Company’s notification to Auxilium of its election not to commercially manufacture XIAFLEX.

Research and development expenses for the second quarter of 2011 were $0.3 million, compared to $0.1 million for the same period in 2010. This increase in research and development expenses was primarily due to higher consulting services related to the Company’s animal study and research and development programs.

General and administrative expenses for the second quarter of 2011 were $1.4 million, compared to $1.6 million for the same period in 2010. The decrease in general and administrative expenses was due to lower stock based compensation and consulting services partially offset by a reversal in the 2010 period of certain third party patent fees reimbursable under the Company’s agreement with Auxilium.

As of June 30, 2011, BioSpecifics had cash and cash equivalents and investments of $10.4 million, compared to $8.5 million on March 31, 2011.

Recent Corporate Highlights:

  • On August 1, 2011, Auxilium reported that XIAPEX is now available for sale in Austria, Denmark, Finland, Germany, Norway, Sweden, and the United Kingdom, and was recently approved in Switzerland. BioSpecifics will receive 8.5% of the up to $22.5 million in additional regulatory milestone payments that Auxilium receives from Pfizer for Dupuytren’s contracture, following Pfizer's first sale of XIAPEX in each of the remaining major markets of the EU. To date, the Company has received $2.5 million in May 2011 for the commercial launch in the United Kingdom and $637,000 for the commercial launch in Germany in June 2011.

  • In June 2011, BioSpecifics announced that positive data for XIAPEX were presented at the XVIth Annual Federation of European Societies for Surgery of the Hand Congress which took place in Oslo, Norway on May 26 – 28, 2011. Pfizer conducted a satellite symposium on XIAPEX treatment for Dupuytren’s contracture.

  • In June 2011, the Company announced that its Board of Directors reauthorized BioSpecifics’ stock repurchase program under which the Company is authorized to repurchase up to $2 million of its outstanding common stock. This decision reflected the Company's continued commitment to increasing value for its stockholders and its confidence that it will achieve its goals.

  • Upcoming Milestones

  • There will be  presentations and workshops discussing XIAFLEX at the upcoming American Society for Surgery of the Hand (ASSH) 2011 Annual Meeting on September 8-11, 2011 in Las Vegas, NV including the following:
  • Pre-conference workshop on reimbursement titled “Implementing the XIAFLEX (collagenase Clostridium histolyticum) Treatment Cycle: Reimbursement from Diagnosis to Treatment” as well as a workshop titled “Training for the Proper Administration of XIAFLEX (collagenase Clostridium histolyticum).”
  • Workshop by Dr. Gary Pess on proper administration of XIAFLEX and Drs. Kurt Anderson, Mark Belsky, Randal Culp and Philip Konkel will provide a XIAFLEX case study workshop.
  • XIAFLEX procedure workshop led by Dr. Arthur Taylor.
  • Auxilium-sponsored investor event featuring key opinion leaders.

  • Auxilium expects to complete the active dosing phase for its Peyronie’s disease Phase 3 double-blind placebo-controlled program at the end of August 2011 and anticipates reporting top-line data in the second quarter of next year. Auxilium believes that potentially 3-5% of the adult Caucasian male population is affected by this disease.

  • Auxilium plans to advance new pipeline indication(s) for XIAFLEX.

  • Webcast and Conference CallThe Company will host a conference call today at 8:30 am EDT to discuss its second quarter 2011 results.

    To participate in the conference call, please dial 800-860-2442 (domestic) or 412-858-4600 (international). The presentation will be available via a live webcast at:

    A replay of the call will be available one hour after the conference ends on August 9, 2011 until 9:00 am EDT on August 19, 2011. To access the replay, please dial 877-344-7529 (domestic) or 412-317-0088 (international) and reference the access code 10002978. The archived webcast will be available for 90 days in the Investor Relations section of the BioSpecifics' website at

    About BioSpecifics Technologies Corp.BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications, three of which include: Dupuytren's contracture; Peyronie's disease; and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. markets XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture. Pfizer, Inc. is responsible for marketing XIAPEX® in 46 countries in Eurasia and Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan. More information about the Company may be found on its website at

    Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding BioSpecifics’ strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, its expected revenue growth, and any other statements containing the words "believes," "expects," "anticipates," "plans," "estimates" and similar expressions, are forward-looking statements. There are a number of important factors that could cause its actual results to differ materially from those indicated by such forward-looking statements, including the statements made by BioSpecifics and by its partner Auxilium regarding progress toward achievement of Auxilium’s objectives for the US launch of XIAFLEX® for Dupuytren’s contracture; the ability of Pfizer to achieve its objectives for XIAPEX® in Europe; the ability of Asahi Kasei to achieve its objectives for XIAFLEX® in Japan; the success of the Phase 3 trials for XIAFLEX for the treatment of Peyronie’s disease; the Company’s ability to initiate and complete clinical trials in additional indications, all of which will determine the amount of milestone, royalty and sublicense income BioSpecifics may receive; and other risk factors identified in the Company's Form 10-K for the year ended December 31, 2010 and its reports on Form 8-K filed with the SEC. All forward-looking statements included in this press release are made as of the date hereof, and the Company assumes no obligation to update these forward-looking statements. BioSpecifics Technologies Corp.Consolidated Statements of Operations(Unaudited)Three months endedSix months endedJune 30, June 30, 2011201020112010Revenues:   Net sales$
    27,145   Royalties1,706,166507,3222,651,247539,134   Licensing revenues3,296,776259,2764,156,0512,807,560   Consulting fees-70,00046,667140,000Total Revenues5,008,824854,8076,865,7393,513,839Costs and expenses:   Research and development270,799144,799482,8651,041,616   General and administrative1,418,0161,646,1652,927,5423,680,343Total costs and expenses1,688,8151,790,9643,410,4074,721,959Operating income (loss)3,320,009(936,157)3,455,332(1,208,120)Other income (expense):   Interest Income16,68825,92533,24851,775   Other income (expense)14,479-14,479-31,16725,92547,72751,775Income (loss) before income tax3,351,176(910,232)3,503,059(1,156,345)   Income tax benefit (expense)(781,835)-2,757,405(8,067)Net income (loss)$ 2,569,341$
    (910,232)$6,260,464$(1,164,412)Basic net income (loss) per share$
    (0.19)Diluted net income (loss) per share$
    (0.19)Shares used in computation of basic net income (loss) per share6,354,1356,273,9456,324,1686,244,136Shares used in computation of diluted net income (loss) per share7,174,5686,273,9457,158,0246,244,136BioSpecifics Technologies Corp.Selected Consolidated Balance Sheet Data (Unaudited)June 30,December 31,20112010Cash and cash equivalents$
    2,470,852Short term investments5,360,9705,360,970Accounts and income tax receivable, net1,062,0772,171,511Deferred tax assets (short and long-term)3,103,944-Working capital10,712,9895,990,899Total assets16,115,70711,518,701Long-term liabilities495,070713,619Total stockholders' equity13,438,7356,700,723

    SOURCE BioSpecifics Technologies Corp.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. BioSpecifics Technologies Corp. Announces Board Authorization of up to $2 Million Share Repurchase Program
    2. BioSpecifics Technologies Corp. to Present at Jefferies 2011 Global Healthcare Conference
    3. BioSpecifics Announces Positive XIAPEX® Data Presented at XVI Annual Federation of European Societies for Surgery of the Hand Congress
    4. BioSpecifics Technologies Corp. Provides Update on XIAPEX® Launch Progress in EU
    5. BioSpecifics Technologies Corp. to Present at SEVEN, Noble Financial Capital Markets Seventh Annual Equity Conference
    6. BioSpecifics Technologies Corp. Announces Launch of XIAPEX® by Pfizer for Treatment of Dupuytrens Contracture in Europe
    7. BioSpecifics Technologies Corp. to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference
    8. BioSpecifics Technologies Corp. Amends Its Rights Agreement
    9. BioSpecifics Technologies Corp. to Present at Lazard Capital Markets 7th Annual Healthcare Conference
    10. BioSpecifics Technologies Corp. Awarded Two Qualifying Therapeutic Discovery Project Grants
    11. BioSpecifics Technologies Corp. to Present at BioCentury Newsmakers in the Biotech Industry Conference
    Post Your Comments:
    (Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
    (Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
    (Date:9/22/2017)... 2017 AVACEN Medical (AVACEN) announced that its ... helping those with the widespread pain associated with fibromyalgia ... in Essex, England commented, "I ... experiencing no sleep at all, tremendous pain, with every ... recommend [the AVACEN 100] enough, how this has and ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
    (Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
    (Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
    (Date:10/12/2017)... ... , ... HMP , a leader in healthcare events and education, today announced ... Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie ... competition recognizes editorial and design excellence across a range of sectors. This year’s program ...
    (Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
    Breaking Medicine News(10 mins):